Vitiligo, manifested by skin hypopigmentation, is an autoimmune disorder of the due to destruction melanocytes. Nivolumab, which a programmed cell death–1 receptor inhibitor, well-known therapy for melanoma. Nivolumab-induced vitiligo has been described in literature, explained non-cancerous This considered favorable response, correlated stronger immune response against tumor cells. The average...